CACanada
Health Canada peptide seizures find bacteria in vials from a Shanghai supplier and an Ottawa shop
Two Health Canada advisories six days apart found bacteria in unauthorized injectable peptides, one case covering more than 11,400 vials. The department says research labels do not make the products legal.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itHealth Canada found bacteria in unauthorized injectable peptides in two enforcement cases six days apart, one involving more than 11,400 seized vials.
Health Canada peptide seizures in November turned up bacteria in vials from two separate cases. The department reported contamination first in products tied to a Shanghai-based online supplier on 6 November, then in a vial taken from an Ottawa wellness business in an advisory issued six days later. Both notices carry one message for consumers: injectable peptides sold without a drug identification number are illegal in Canada, and a label saying the vial is meant for research changes nothing. The first case alone involved more than 11,400 seized vials.
Two advisories six days apart
On 6 November Health Canada posted a warning about contaminated injectable peptides sold online by a company based in Shanghai. Using court-issued entry warrants, inspectors took product from two Canadian websites that had resold it, and the total from the supplier and the two sites came to more than 11,400 vials. The notice lists six products: human chorionic gonadotropin, MOTS-c, NAD+, retatrutide, tesamorelin and tirzepatide. Laboratory tests on seized material identified three bacteria, Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes, the last also known by its older name Propionibacterium acnes. Health Canada said both Canadian websites are no longer active and that it has asked the Shanghai company to stop selling illegal peptides into Canada at once.
The second advisory followed on Thursday 12 November and concerned a single business in Ottawa, Ontario. According to Benefits and Pensions Monitor and the Daily Mail, which both reported on the notice, Health Canada acted after a consumer complaint that the shop was offering unauthorized products in its store and online. The advisory names ten injectable peptides and one oral capsule sold as BPC-157. Testing found Sphingomonas aquatilis/melonis in one seized vial, a microbe that normally lives in water and soil and rarely harms healthy people unless it enters the body through a wound or needle. The business agreed to stop selling through both channels. Reports say the list pairs BPC-157 with TB-500 and that some vials carried a "For Research Purposes Only" label.
Why the research label does not help
Health Canada rejected the research-only defence in plain terms. Both advisories say such wording does not make a product legal and does not exempt it from the rules. The department's guidance on peptide regulation, updated on 23 October, sets out the basis. Peptide products can fall under drug rules or natural health product rules depending on their use, makeup and route, but any peptide meant for injection is treated as a drug under the Food and Drug Regulations. A legal product carries an eight-digit drug identification number, or a natural product number for the items that qualify, and an unauthorized product has neither. That number is the quickest check a Canadian patient or pharmacist can make, because it shows the product passed a federal review.
That number is the quickest check a Canadian patient or pharmacist can make, because it shows the product passed a federal review.
The tirzepatide vials show why the label matters more than the molecule. Tirzepatide is an authorized medicine in Canada, sold as Mounjaro and Zepbound, and semaglutide is authorized as Ozempic, Rybelsus and Wegovy, as Benefits and Pensions Monitor noted. Yet vials of tirzepatide with no drug identification number are as illegal as vials of retatrutide, which has no approval in Canada or the United States. Health Canada warned that injecting contaminated peptides can lead to serious infection, hospital care and, in severe cases, sepsis. It also listed hormone disruption, liver or kidney damage, blood clots and tumour growth among the wider risks of unauthorized peptides, and it advised anyone who develops fever, chills, redness or swelling after use to get medical help.
Health Canada peptide seizures and the enforcement toolkit
The Health Canada peptide seizures fit a pattern the department describes in its guidance. Complaints about the sale and promotion of unauthorized peptides have risen, especially online, and the department says it is answering with recalls, seizures, requests to stop selling, ministerial orders to halt advertising and sale, entry warrants issued by courts and permanent injunctions. Earlier in 2026 it obtained a permanent injunction from a Quebec court against an online seller of injectable peptides. The November actions add laboratory results to that list, and those results give the department a safety case that goes beyond paperwork. A missing drug number is a legal problem, while a vial that grows bacteria is a medical one, and the advisories now put both in front of consumers.
Border control is the other half of the effort. Health Canada says it is working with the Canada Border Services Agency to stop unauthorized shipments, and its guidance warns that imports which fail the rules may be refused entry, detained or seized depending on the risk they pose. That matters because the first November case traced back to a supplier outside the country, with Canadian websites acting as resellers. The department also says it is coordinating with provincial and territorial regulators over peptides that are compounded inside Canada. Its guidance states that compounding must not be used to avoid federal review, that compounded products should be tied to an individual patient and not advertised to the public, and that some activity called compounding can amount to drug manufacturing.
| Date | Health Canada action | Products named | Laboratory finding |
|---|---|---|---|
| 23 Oct 2026 | Peptide guidance updated | All injectable peptides treated as drugs | Not applicable |
| 6 Nov 2026 | Advisory on a Shanghai supplier and two Canadian websites, over 11,400 vials seized | hCG, MOTS-c, NAD+, retatrutide, tesamorelin, tirzepatide | Acinetobacter seifertii, Acinetobacter nosocomialis, Cutibacterium acnes |
| 12 Nov 2026 | Advisory on an Ottawa wellness business after a complaint | Ten injectable peptides and BPC-157 capsules | Sphingomonas aquatilis/melonis in one vial |
How Canada differs from the US route
The Canadian line is tightening while the United States moves in another direction. On 28 October the US health department placed an interim policy in the Federal Register under which, for now, it will not act against licensed pharmacies and physicians that compound six unapproved peptide ingredients, BPC-157 and TB-500 among them, according to Reuters. The six were among seven reviewed in July by an FDA advisory committee on pharmacy compounding, which backed six of them by narrow votes. None of that changes Canadian law. In Canada an injectable peptide without authorization stays illegal to sell, and nothing in the October guidance points to a similar allowance. Readers in Canada should treat American headlines about compounding access as foreign news with no effect at home.
For Canadian patients the practical message is narrow. Approved peptide medicines such as insulin, semaglutide and tirzepatide reach people through prescriptions and pharmacies, with a drug identification number on the label that can be checked in the Drug Product Database run by Health Canada. Products sold through wellness shops, social media or websites that ship vials with research labels do not pass through that system, and the November tests show what can be inside them. The same pattern has surfaced abroad. British regulators have reported counterfeit weight loss pens packed at scale. In Australia, a coroner has sought a regulator review after a death linked to peptides. Canada so far relies on seizures, testing and public warnings.
Conclusion
The Health Canada peptide seizures of November moved the argument from legal status to laboratory evidence. Two advisories, six days apart, found bacteria in vials sold through a foreign supplier and a local shop. What to watch next is whether the department turns to ministerial orders or new injunctions, and whether border seizures rise as the Canada Border Services Agency steps up checks. Health Canada has not said whether any user fell ill.
Why it matters in Canada
Injectable peptides are always drugs in Canada and need a drug identification number. Lab-confirmed bacteria give Health Canada a safety case on top of the legal one, and the vials included tirzepatide, an approved medicine sold here only under its authorized brands.
What to watch
Whether Health Canada issues ministerial orders or new court injunctions against other sellers, and whether border seizures with the Canada Border Services Agency increase.
Sources
- Health Canada: Health Canada warns about contaminated, unauthorized injectable peptides (advisory RA-82930, 6 November 2026)
- Health Canada: Peptides, regulation and enforcement (updated 23 October 2026)
- Benefits and Pensions Monitor: Health Canada seizes unauthorized peptide vials six days apart
- Daily Mail: Urgent warning over illegal peptides seized in Canada
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.